Guardant Health reveals Shield CRC test study data
The study's findings revealed that the Shield test identified 83% of individuals with CRC.
14 March 2024
14 March 2024
The study's findings revealed that the Shield test identified 83% of individuals with CRC.
The company’s Amplify is a new class of synthetic biomaterials designed to optimise cell proliferation and bone formation.
The robotic surgery platform is aimed at speeding up aortic valve replacement surgeries while cutting down on staff.
Anastrozole works by reducing oestrogen levels in post-menopausal women, which can otherwise promote breast cancer cell growth.
Odne's new technology platform for root preservation therapy is anticipated to transform the field of endodontics.
The device, currently being tested in a trial for rheumatoid arthritis, will next enter a trial for multiple sclerosis patients.
Sooma’s transcranial direct current stimulation device uses electrical current to stimulate the brain and alleviate depression symptoms.
Exact Sciences submitted a pre-market approval application for the device to the FDA in December 2023.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.